Comparative Pharmacology
Head-to-head clinical analysis: COARTEM versus QUIOFIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COARTEM versus QUIOFIC.
COARTEM vs QUIOFIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Artemether and lumefantrine are antimalarial agents that act as blood schizonticides. Artemether is rapidly metabolized to dihydroartemisinin, which generates free radicals that damage parasite proteins and membranes. Lumefantrine inhibits the formation of beta-hematin (hemozoin) by forming a complex with hemin, thereby preventing parasite detoxification of heme.
QUIOFIC (difelikefalin) is a selective agonist of the kappa-opioid receptor (KOR). Activation of KOR on peripheral sensory neurons and immune cells inhibits the release of pro-inflammatory mediators and reduces pruritus signaling, particularly in chronic kidney disease-associated pruritus.
4 tablets (each containing artemether 20 mg and lumefantrine 120 mg) orally twice daily for 3 days (total of 6 doses). Doses should be taken with fatty food to enhance absorption. Repeat dosing if vomiting occurs within 1 hour after administration.
Quiofic (diroximel fumarate) 462 mg orally twice daily.
None Documented
None Documented
Artemether: terminal elimination half-life ~1–3 hours (rapid, consistent with its role in rapid parasite clearance). Lumefantrine: terminal elimination half-life ~4–6 days (mean 4.5 days in healthy volunteers; longer in malaria patients due to increased Vd and protein binding). The prolonged half-life of lumefantrine ensures effective post-treatment prophylaxis.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged to 30-50 hours in severe renal impairment (CrCl <30 mL/min).
Artemether is primarily metabolized in the liver via CYP3A4; its metabolites are excreted in feces (approximately 80%) and urine (minor). Lumefantrine is also hepatically metabolized (CYP3A4) and excreted predominantly in feces (90%) with minimal renal excretion (<1%). Overall, both drugs are eliminated mainly via biliary/fecal routes. Renal excretion is negligible.
Primarily renal as unchanged drug (60-70%) and as active metabolite (10-15%); biliary/fecal excretion accounts for 15-20%.
Category C
Category C
Antimalarial Agent
Antimalarial Agent